GLPwatch
Zepbound for Obstructive sleep apnea
tirzepatide · FDA-approved
Last updated 2026-05-28 15:46 UTCZepbound (tirzepatide) is FDA-approved for obstructive sleep apnea.
AI summary of the sources below.
| Drug | Zepbound (tirzepatide) |
|---|---|
| Condition | Obstructive sleep apnea |
| Approval status | FDA-approved |
| Research papers | 18 |
Zepbound is FDA-approved for obstructive sleep apnea. See the current label on the Zepbound page.
Research on tirzepatide for obstructive sleep apnea (18)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Clinical Impact of Tirzepatide on Patients With OSA and Obesity.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.
- Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.
- Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
- Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
- Tirzepatide (Zepbound) for obstructive sleep apnea.
- [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].
- Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.
- Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.
- [SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.